Enteric-Coated Formulations: Gastric Resistance Design Principles

A proton pump inhibitor that degrades the moment it meets stomach acid is worthless to the patient who swallows it. So is an enteric coated aspirin that dissolves in the stomach and triggers the very gastric irritation it was designed to avoid. These failures are not rare laboratory curiosities — they are the everyday risk that any team developing an enteric coated formulation has to engineer against. Sound enteric coated formulation design is the discipline of guaranteeing that a dosage form survives the acid of the stomach completely intact, then releases its drug cleanly once it reaches the small intestine.

The cost of getting this wrong is rarely a single rejected batch. An under-cured enteric film can pass its acid-resistance test at release and then quietly fail it three months into stability, after the product is already on the market. A coating weight set without margin can pass on average while a fraction of every batch leaks acid into units that never should. The defining quality attribute of these products — gastric resistance — is invisible to the eye and provable only by a specific test, which is exactly why it demands deliberate design rather than trial and error.

This article sets out the design principles that make gastric resistance reliable: the polymer chemistry that responds to pH, the coating weight and film continuity that determine whether acid gets in, the curing step that aqueous systems cannot skip, the choice between coating a whole tablet or hundreds of pellets, and the dissolution test that is the final arbiter. It is written for formulators and process engineers who need the mechanism and the engineering, not marketing copy — drawing on established pharmacopoeial methods and well-documented coating science throughout.

Why Gastric Resistance Matters in Formulation Design

Gastric resistance exists to solve two distinct clinical problems, and recognising which one a project is solving shapes every downstream decision. Some drugs are chemically destroyed by acid — proton pump inhibitors, certain peptides and enzymes, and acid-labile antibiotics lose potency in the stomach and must be shielded until they pass into the intestine. Other drugs are chemically stable but locally aggressive, irritating or ulcerating the gastric mucosa if they dissolve there, which is the case for many non-steroidal anti-inflammatory drugs. In both situations the coating delays release until pH rises, but the consequences of failure differ, and the formulation strategy follows from that.

An enteric coating is fundamentally a pH-triggered switch, not a timed-release device. It is designed to do nothing for a fixed period and then act decisively when the environment changes. The design targets behaviour at two extremes — total impermeability at gastric pH and rapid dissolution at intestinal pH — rather than a smooth release curve. This binary character is what makes the coating's continuity so unforgiving: a film that is 95% perfect still admits acid through its 5% of pores.

• Acid-labile drug protection — Shields drugs that degrade below pH 3–4 so they reach the intestine with potency intact.
• Gastric mucosa protection — Prevents locally irritant drugs from dissolving against the stomach wall.
• Targeted intestinal delivery — Directs release to the duodenum, jejunum, or colon by choosing a polymer with the matching dissolution pH.
• Taste and odour avoidance for the upper GI tract — Keeps the drug sealed until past the point of gastric contact.

Enteric Polymer Chemistry: The Acid-Group Backbone

Every enteric polymer in routine pharmaceutical use shares one structural feature: free carboxylic acid groups distributed along the polymer chain. These groups are the entire basis of pH-dependent solubility, because their ionisation state changes with the surrounding pH. At the low pH of gastric fluid the carboxylic acid groups stay protonated and uncharged, leaving the polymer hydrophobic and insoluble; at higher intestinal pH they ionise to carboxylate anions, the chain becomes hydrophilic, and the film dissolves. Choosing among the available polymers is largely a matter of matching the polymer's dissolution pH threshold to the intended release site, then weighing process and regulatory factors.

The dominant chemistries fall into two families. Methacrylic acid copolymers — the Eudragit L and S grades — are copolymers of methacrylic acid with an ester comonomer, and the ratio of acid to ester sets the dissolution threshold. The cellulose-derived enteric polymers, including cellulose acetate phthalate, hypromellose phthalate, and hypromellose acetate succinate, attach acidic phthalate or succinate groups to a cellulose backbone. The newer hypromellose acetate succinate (HPMCAS) is valued for a high glass transition temperature that resists softening and unwanted coalescence during storage. For a deeper treatment of the coating equipment and film-forming polymers these systems share with non-enteric coats, see our guide to tablet coating technology.

The pH-Trigger Mechanism Along the GI Tract

The reason enteric coatings work at all is the steep pH gradient between the stomach and the small intestine. Fasting gastric fluid sits around pH 1.5 to 3.5, while the proximal small intestine rises to roughly pH 6 and climbs further toward the distal ileum and colon. An enteric polymer is engineered to straddle this gradient: insoluble below its threshold pH and soluble above it. The art of the design is selecting a polymer whose threshold sits comfortably above the highest gastric pH the product will encounter but below the intestinal pH at the intended release site, leaving a reliable margin on both sides.

That margin matters because gastrointestinal pH is not a fixed number. Food raises gastric pH, disease states and acid-suppressing comedication shift it further, and intestinal pH itself varies between individuals and along the bowel. A polymer with a threshold too close to the upper end of the gastric range risks premature dissolution in a fed stomach; one with a threshold too high risks incomplete or delayed release if intestinal pH does not climb as expected. The practical consequence is that polymer selection is a clinical decision as much as a chemical one — the release-site target and the patient population both feed into it.

• Gastric phase — Polymer carboxyl groups protonated; film hydrophobic and impermeable to water and drug.
• Threshold crossing — As pH rises past the polymer's set point, carboxyl groups ionise and the chain turns hydrophilic.
• Intestinal phase — Ionised film hydrates, swells, and dissolves, releasing the drug at the targeted site.

Coating Weight and Film Continuity

The single most important physical determinant of gastric resistance is the continuity of the film, and coating weight is the lever that controls it. Acid does not permeate a properly formed enteric film evenly; it enters through the weakest point — a pore, a crack, or a thin spot on a tablet edge. This means gastric resistance is governed not by the average coating thickness across a batch but by the thinnest, most defective point on any single unit. A formulation can show an excellent average coating weight and still fail because a fraction of units carry a flaw.

For this reason, enteric coating weight is specified per unit of substrate surface area rather than as a simple percentage weight gain, and pellets or granules — with far more surface area per gram than tablets — require proportionally more coating. The minimum viable coating weight is established experimentally as the point at which acid resistance is first reliably achieved, and the specification is then set with a deliberate safety margin above it. Pushing coating weight higher improves acid resistance but eventually delays intestinal release, so the design lives in a window bounded below by acid failure and above by sluggish release.

Curing and Film Coalescence in Aqueous Systems

Aqueous enteric coatings are sprayed as dispersions of fine, discrete polymer particles suspended in water, and a continuous film only exists once those particles fuse together. As water evaporates the particles pack and begin to coalesce, but coalescence is a time- and temperature-dependent process that is seldom complete by the end of spraying. A curing step — holding the coated units at a controlled elevated temperature, sometimes at defined humidity, for a set period — drives the film to its fully fused, low-porosity end state. Skipping or shortening this step leaves a porous film that lets acid through.

The insidious feature of inadequate curing is that the product can pass its acid-resistance test at release and then fail later. An under-cured film keeps slowly coalescing during storage, so its porosity and acid resistance drift over the shelf life — a latent defect that surfaces only on stability. Curing temperature must sit above the minimum film-forming temperature of the plasticised polymer, yet below any temperature that would soften the drug or the tablet core. Because of this, curing time and temperature are treated as critical process parameters, formally validated, and confirmed by testing acid resistance on cured material across stability.

• Coalescence — Polymer particles must fuse into a continuous film; spraying alone rarely completes it.
• Curing window — Temperature above the plasticised minimum film-forming temperature but below core/drug softening limits.
• Stability risk — Under-cured films continue to coalesce in storage, so acid resistance changes after release.
• Validation — Curing time and temperature are critical process parameters confirmed against the stability programme.

Tablets, Capsules and Multiparticulate Systems

Gastric resistance can be built into several dosage-form architectures, and the choice has a large effect on how robust and reproducible the result is. The simplest route is to enteric coat a whole tablet in a perforated coating pan, but this creates an all-or-nothing unit: if the coat on a single tablet is breached, that entire dose is exposed to acid. Multiparticulate systems instead distribute the dose across hundreds of independently coated pellets, so a flaw on a few pellets barely registers in the overall acid-resistance result and gastric emptying becomes far more reproducible. This contrast in robustness is one of the central trade-offs in enteric design.

Multiparticulate systems are produced by drug-layering and enteric-coating pellets in a fluid-bed coater, then filling them into capsules or compressing them into tablets that disintegrate to release the coated pellets. The approach also smooths out the variability of gastric emptying, since many small units empty more steadily than one large tablet that may be held in the stomach. The cost is process complexity and the higher coating demand of the larger surface area. The principles connect closely to broader release-control strategy, covered in our guide to modified-release tablet technology, and to the wider formulation support available through our pharmaceutical product development services.

Dissolution Testing: The Proof of Gastric Resistance

Gastric resistance is not a property you can confirm by inspection — it is proven only by a specific two-stage dissolution test, and that test is the formal arbiter of whether an enteric coated product works. The method, described in USP <711> and the equivalent European Pharmacopoeia chapter 2.9.3, runs the dosage form first through an acid stage and then through a buffer stage using the standard paddle or basket apparatus. The acid stage simulates gastric exposure; the buffer stage simulates the intestinal environment where release should occur. A product that fails either stage is, by definition, not performing as an enteric formulation.

In the acid stage the units are held in 0.1 N hydrochloric acid (about pH 1.2) for two hours, and the acceptance criterion is that no more than 10% of the drug dissolves. The medium is then changed to a buffer near pH 6.8 — the buffer stage — and the product must release the labelled amount within a defined time, commonly not less than 80% within 45 to 60 minutes. Because this test defines the product's critical quality attribute, it is run at development to set the coating window, at release to clear each batch, and across stability to catch the latent under-curing failures that only emerge over time. The FDA and ICH dissolution guidances frame how these methods are developed and validated.

Coating Defects and Root-Cause Diagnosis

When an enteric product fails its acid stage, the discipline that separates an efficient fix from weeks of wasted batches is correct root-cause diagnosis. Acid failure almost always traces back to a breach in film continuity rather than to the wrong polymer, and the breach has a small number of recognisable causes. The right response is to identify which mechanism is at work — by weighing the coat, inspecting the film under magnification, and checking the curing record — and then correct that specific cause, rather than reflexively raising the coating weight and hoping the problem disappears.

Each defect maps to a process or formulation variable, and treating the symptom without the cause tends to create new problems. Over-plasticising to stop cracking can leave a tacky film; over-coating to compensate for pores can delay intestinal release. A structured development approach — characterising the coating window against coating weight, spray rate, drying conditions, and curing — is the established way to prevent these failures during development rather than firefight them in production. For projects that need experienced support setting that window, our team offers pharmaceutical formulation development services spanning polymer selection through scale-up.

• Insufficient coating weight — Average film too thin to seal every unit. Correction: establish minimum weight experimentally and add a margin.
• Cracking — Brittle film from inadequate plasticisation or thermal stress. Correction: adjust plasticiser type or level; soften drying and curing ramps.
• Pores / spray-drying — Droplets dry before coalescing. Correction: lower inlet temperature, adjust atomisation, raise spray-zone humidity.
• Edge and logo coverage gaps — Thin film at tablet edges or debossing. Correction: optimise pan speed and spray pattern; consider rounded core geometry.
• Under-curing — Porous film that fails on stability. Correction: validate curing time and temperature; confirm acid resistance on cured material.
• Missing seal coat — Acidic or hygroscopic core interacts with enteric layer. Correction: apply a sub-coat between core and enteric film.

Absar Khan

Absar Khan is the Founder and Lead Consultant at Global Formulation, specialising in pharmaceutical, cosmetic, and industrial chemical product development. With hands-on experience across solid dosage formulation, coating and enteric technology, aerosol systems, and lubricant chemistry, Absar helps entrepreneurs and manufacturers develop, scale, and commercialise formulated chemical products. Connect on LinkedIn.